Conceptos Categóricos

abelson.jpg Mark B Abelson
Columnista Experto de SIIC

At Harvard: Associate Clinical Professor At Schepens: Senior Clinical Scientist Ophthalmology, Department of Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, EE.UU.
Columnista Experto de SIIC Mark B Abelson en colaboración con

Fecha de aprobación: 11 de abril, 2006
Primera edición en siicsalud: 27 de octubre, 2006
Sección Artículos originales, subsección Expertos de Iberoamérica,
página /des/expertocompleto.php/80892  
Especialidad principal: Especialidad principalOftalmología

Especialidades relacionadas:
Alergia,Farmacología,Medicina Farmacéutica,Medicina Interna,

  • Berger W, Abelson MB, Gomes PJ et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy., Annals of Allergy, Asthma & Immunology. 95(95):361-71, 2005

  • Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, Gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue., Arch Ophthalmol. 123(123):1282-3, 2005

  • Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis., Curr Med Res Opin. 21(21):683-91, 2005

  • Ousler GW, Wilcox KA, Gupta G, Abelson MB. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride., Annals of Allergy, Asthma & Immunology 93:460-464, 2004

  • Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population., Pediatr Allergy Immunol. 15(15):551-7, 2004

  • Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration., Allergy Asthma Proc. 25(25):69-75, 2004

  • Mark B Abelson Los suscriptores, miembros de SIIC y socios del Círculo de Lectores pueden solicitar información adicional. Para enviarla, SIIC solicitará aprobación del autor.

    Dirección profesional:

    863 Turnpike St. - MA 01845, North Andover, EE.UU.